Vargas-Beltran AM, Mialma-Omana SJ, Vivanco-Tellez DO. Targeting gut microbiota in liver disease: A pharmacological approach for hepatic encephalopathy and beyond. World J Gastrointest Pharmacol Ther 2025; 16(4): 110271 [DOI: 10.4292/wjgpt.v16.i4.110271]
Corresponding Author of This Article
Andres Manuel Vargas-Beltran, MD, Department of Hepatology, General Hospital Dr. Manuel Gea Gonzalez, Calz. de Tlalpan 4800, Belisario Domínguez Secc 16, Mexico City 14080, Ciudad de México, Mexico. andresman.vargas@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 5, 2025 (publication date) through Dec 9, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Vargas-Beltran AM, Mialma-Omana SJ, Vivanco-Tellez DO. Targeting gut microbiota in liver disease: A pharmacological approach for hepatic encephalopathy and beyond. World J Gastrointest Pharmacol Ther 2025; 16(4): 110271 [DOI: 10.4292/wjgpt.v16.i4.110271]
World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 110271 Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110271
Targeting gut microbiota in liver disease: A pharmacological approach for hepatic encephalopathy and beyond
Andres Manuel Vargas-Beltran, Stuart Javier Mialma-Omana, Diego Omar Vivanco-Tellez
Andres Manuel Vargas-Beltran, Department of Hepatology, General Hospital Dr. Manuel Gea Gonzalez, Mexico City 14080, Ciudad de México, Mexico
Andres Manuel Vargas-Beltran, Stuart Javier Mialma-Omana, Diego Omar Vivanco-Tellez, Faculty of Medicine, Meritorious Autonomous University of Puebla, Puebla 72420, Puebla, Mexico
Stuart Javier Mialma-Omana, Department of Surgery, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City 14080, Ciudad de México, Mexico
Author contributions: Vargas-Beltran AM, Mialma-Omana SJ, and Vivanco-Tellez DO wrote the manuscript and prepared the figures; Vargas-Beltran AM revised and polished the manuscript as a co-corresponding author and was responsible for the submission of the current version of the manuscript; All authors read and approved the final manuscript.
Conflict-of-interest statement: All authors have no conflicts of interest to declare for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Andres Manuel Vargas-Beltran, MD, Department of Hepatology, General Hospital Dr. Manuel Gea Gonzalez, Calz. de Tlalpan 4800, Belisario Domínguez Secc 16, Mexico City 14080, Ciudad de México, Mexico. andresman.vargas@gmail.com
Received: June 4, 2025 Revised: July 4, 2025 Accepted: September 28, 2025 Published online: December 5, 2025 Processing time: 184 Days and 19.5 Hours
Core Tip
Core Tip: The gut microbiota is a key player in the progression of liver diseases, especially hepatic encephalopathy, by influencing ammonia levels, inflammation, and neurocognitive function. This review discussed current and emerging therapies that target the gut-liver axis, including non-absorbable disaccharides, antibiotics, probiotics, synbiotics, postbiotics, and fecal microbiota transplantation. Novel agents such as bile acid modulators and microbiome-targeted molecules were also explored. Modulating gut microbiota may not only alleviate hepatic encephalopathy but also benefit conditions like metabolic dysfunction-associated steatotic liver disease and cirrhosis, facilitating the way for more personalized and effective liver disease management strategies.
